Ceftazidime

Revision as of 18:04, 10 June 2009 by Brian Blank (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Ceftazidime
Clinical data
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
administration
Intravenous, intramuscular
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
Pharmacokinetic data
Bioavailability91% (IM)
Metabolismnegligible
Elimination half-life1.6–2 hours
Excretion90–96% renal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H22N6O7S2
Molar mass546.58 g/mol

WikiDoc Resources for Ceftazidime

Articles

Most recent articles on Ceftazidime

Most cited articles on Ceftazidime

Review articles on Ceftazidime

Articles on Ceftazidime in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ceftazidime

Images of Ceftazidime

Photos of Ceftazidime

Podcasts & MP3s on Ceftazidime

Videos on Ceftazidime

Evidence Based Medicine

Cochrane Collaboration on Ceftazidime

Bandolier on Ceftazidime

TRIP on Ceftazidime

Clinical Trials

Ongoing Trials on Ceftazidime at Clinical Trials.gov

Trial results on Ceftazidime

Clinical Trials on Ceftazidime at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ceftazidime

NICE Guidance on Ceftazidime

NHS PRODIGY Guidance

FDA on Ceftazidime

CDC on Ceftazidime

Books

Books on Ceftazidime

News

Ceftazidime in the news

Be alerted to news on Ceftazidime

News trends on Ceftazidime

Commentary

Blogs on Ceftazidime

Definitions

Definitions of Ceftazidime

Patient Resources / Community

Patient resources on Ceftazidime

Discussion groups on Ceftazidime

Patient Handouts on Ceftazidime

Directions to Hospitals Treating Ceftazidime

Risk calculators and risk factors for Ceftazidime

Healthcare Provider Resources

Symptoms of Ceftazidime

Causes & Risk Factors for Ceftazidime

Diagnostic studies for Ceftazidime

Treatment of Ceftazidime

Continuing Medical Education (CME)

CME Programs on Ceftazidime

International

Ceftazidime en Espanol

Ceftazidime en Francais

Business

Ceftazidime in the Marketplace

Patents on Ceftazidime

Experimental / Informatics

List of terms related to Ceftazidime

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ceftazidime (INN) (IPA: Template:IPA) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negative bacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections. Ceftazidime pentahydrate is marketed under various trade names including Fortum (GSK).

Clinical use

Ceftazidime is usually reserved for the treatment of infections caused by Pseudomonas aeruginosa. It is also used in the empirical therapy of febrile neutropenia, in combination with other antibiotics. The usual dose is 1–2 g IV/IM every 8–12 hours(2 - 3times), though this can vary by the indication, infection severity, and/or renal function of the recipient.

Chemistry

In addition to the syn-configuration of the imino side chain, compared to other third-generation cephalosporins, the more complex moiety (containing two methyl and a carboxylic acid group) confers extra stability to β-lactamase enzymes produced by many Gram-negative bacteria. The extra stability to β-lactamases increases the activity of ceftazidime against otherwise resistant Gram-negative organisms including Pseudomonas aeruginosa. The charged pyridinum moiety increases water-solubility.

See also

Template:SIB th:เซฟตาซิดิม

Template:WS